An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents-Reference-Cited by-同舟云学术

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: A three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents

Published:2011-01-28 Issue:2 Volume:63 Page:337-345
ISSN:0004-3591
Container-title:Arthritis & Rheumatism
language:en
Short-container-title:Arthritis & Rheumatism

Author:

Genovese Mark C.,Kavanaugh Arthur,Weinblatt Michael E.,Peterfy Charles,DiCarlo Julie,White Michael L.,O'Brien Maryann,Grossbard Elliott B.,Magilavy Daniel B.

Publisher

Wiley

Subject

Pharmacology (medical),Immunology,Rheumatology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/art.30114/fullpdf

Reference14 articles.

1. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis;Felson;Arthritis Rheum,1995

2. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition;Genovese;N Engl J Med,2005

3. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks;Cohen;Arthritis Rheum,2006

4. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial;Emery;Ann Rheum Dis,2008

5. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial;Smolen;Lancet,2009

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ADVANCES IN IMAGING FOR CLINICAL TRIALS IN RHEUMATIC DISEASES;Proceeding of the Shevchenko Scientific Society. Medical Sciences;2023-12-22

2. An Update on the Emerging Role of Wnt/β-catenin, SYK, PI3K/AKT, and GM-CSF Signaling Pathways in Rheumatoid Arthritis;Current Drug Targets;2023-12

3. Rasch Analysis of Joint Replacement Version for Hip Disability and Osteoarthritis Outcome in Individuals With Advanced Osteoarthritis of Hip Awaiting Total Hip Arthroplasty Surgery;Archives of Physical Medicine and Rehabilitation;2023-12

4. Preclinical Pharmacology Characterization of Sovleplenib (HMPL-523), an Orally Available Syk Inhibitor;Journal of Pharmacology and Experimental Therapeutics;2023-11-02

5. Epstein–Barr virus and genetic risk variants as determinants of T-bet+ B cell-driven autoimmune diseases;Immunology Letters;2023-09